PACTR201303000499409已完成未知
Efficacy Study of ChAd63-MVA ME-TRAP prime-boost Vaccination against Plasmodium
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 160
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 Year(s) 至 50 Year(s)（—）
- 性别
- Male
入选标准
- •Consenting adult males aged 18-50 yrs in good health.
- •Will remain resident in the study area for the study duration.
- •Able and willing (in the investigators opinion) to comply with all study requirements
- •Informed consent.
排除标准
- •1. Any significant medical disease, disorder, finidng which may significantly increase the risk of the volunteer because of participantion in the sutdy, affect the ability of the volunteer to participate in the study or impair tinterpretation of the study data.
- •2. Hypersensitivity to HDCRV, the tiral vaccine or the antimalarial use.
- •3. History of allergic disease or reactions likely to be exacerbated by any component of the vaccines, eg egg products, kathon, neomycin
- •4. Haemoglobin <10 g/dl
- •5.Clinically significant abnormalities of laboratory screening tests (full blood count, ALT, creatinine levels)
- •6. Blood transfusion within month of enrollemnt
- •7.History of vaccination with previous experimental malaria vaccines or other vaccines likely to impact on findins of study(eg. other MVA or adenovirus vectoredvaccines)
- •8.Administration of any other vaccine or immunoglobulin with 2 wks before vaccination
- •9. HIV or Hep B surface antigen seropositivity
- •10. Current participation in another clin trial of recent participatnin within 12 wks of study
- •11. Any other finding which in opinion of investigators would increase tisk of adverse outcome from participation in trial
- •12. Likihood of travel away from study area
研究者
相似试验
Unknown
不适用
A study to find out if a new malaria vaccine regimen can protect against malaria in African adults.MalariaPACTR201202000356208niversity of Oxford120
招募中
1 期
EvAluation of the efficacy of MaaT013 as salvage theRapy in acute GVHD patiEntS with gastrointestinal involvement, refractory to ruxolitinib; a multi-center open-label phase III trial.Treatment of acute graft-versus host disease (aGvHD) to the gastrointestinal (GI) tract of patients who are resistant or intolerant to ruxolitinib.MedDRA version: 27.0Level: PTClassification code: 10066264Term: Acute graft versus host disease in intestine Class: 100000004870CTIS2024-513023-17-00MaaT PHARMA73
招募中
1 期
Evaluation of the efficacy of MaaT013 as salvage therapy in acute GVHD patients with gastrointestinal involvement, refractory to ruxolitinib; a multi-center open-label phase III trialSalvage therapy of acute GVHD patients with gastrointestinal involvement, refractory to ruxolitinib.MedDRA version: 27.0Level: PTClassification code 10066264Term: Acute graft versus host disease in intestineSystem Organ Class: 10021428 - Immune system disordersEUCTR2021-001841-11-ATMaaT Pharma75
进行中（未招募）
1 期
Evaluation of the efficacy of MaaT013 as salvage therapy in acute GVHD patients with gastrointestinal involvement, refractory to ruxolitinib; a multi-center open-label phase III trialEUCTR2021-001841-11-ESMaaT Pharma75
已完成
1 期
A study to test three experimental HIV vaccines in healthy adultsHIV/AIDSPACTR202006495409011niversity of Oxford88